Trial Profile
An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms LEADe
- Sponsors Pfizer
- 23 Mar 2010 Results published in Neurology.
- 23 Mar 2010 Primary endpoint 'Alzheimer's Disease Assessment Scale' has not been met.
- 23 Mar 2010 Primary endpoint 'Alzheimer's Disease Cooperative Study Clinical Global Impression of Change' has not been met.